Ethyl 4-Bromo-1,3-Thiazole-5-Carboxylate

In the preparation of ATP-competitive kinase inhibitors incorporating a 4-arylthiazole-5-carboxylate pharmacophore, ethyl 4-bromo-1,3-thiazole-5-carboxylate is subjected to palladium-catalyzed Suzuki-Miyaura cross-coupling with arylboronic acids under strictly anhydrous and deoxygenated conditions. The reaction mandates a catalyst system composed of Pd(OAc)₂ loaded at 0.5–1.0 mol% relative to the ester and SPhos at a ligand-to-metal ratio of 2:1, dispersed in pre-sparged THF/deionized water (4:1 v/v) containing K₃PO₄ (2.0 eq). The arylboronic acid nucleophile is introduced at 1.05–1.2 molar equivalents; the slight excess counterbalances protodeboronation losses observed in aqueous base at reaction temperatures of 60–68 °C over 8–14 h. Production-scale batches of 50–120 kg are executed in glass-lined reactors (Pfaudler Type E, 4000 L nominal volume) equipped with a nitrogen purge manifold maintaining headspace oxygen below 5 ppm and a retreat-curve impeller operating at 85–110 rpm. Upon reaction completion confirmed by in-process HPLC (C18 column, 254 nm, bromoester starting material < 1.0 area%), the mixture is filtered through a 0.5 µm celite pad to remove palladium black and residual inorganic salts, followed by a solvent swap to isopropyl acetate and a controlled water wash at 45 °C. The crude product is crystallized from n-heptane/ethyl acetate (5:1 v/v) with a cooling ramp of -0.3 °C/min to -5 °C, yielding the 4-(hetero)arylthiazole-5-carboxylic acid ethyl ester intermediate in 81–92% isolated yield and >99.0% chromatographic purity. Palladium scavenging with a trimercaptotriazine-functionalized silica resin is implemented when the residual metal content measured by ICP-MS exceeds 20 µg/g; the target specification aligns with ICH Q3D Guideline for Elemental Impurities, setting an oral PDE-based control threshold of 10 µg/g for palladium in the intermediate. The terminal output is a family of 4-arylthiazole-5-carboxylate scaffolds furnished to medicinal chemistry groups developing selective c-Met/ALK dual inhibitors and CDK2/9 clinical candidates. From a regulatory standpoint, the brominated aromatic skeleton falls under the structural alerts described in ICH M7(R1) Table 3 (Class 3 monohaloalkene alert); a compound-specific purge factor calculation based on spike-purge experiments demonstrates that the bromide-containing intermediate is cleared to below the threshold of toxicological concern (1.5 µg/day) over the subsequent three synthetic transformations without requiring dedicated control steps.

The ethyl ester moiety undergoes saponification with lithium hydroxide monohydrate (1.05 eq) in a THF/deionized water (3:1 v/v) mixture at a jacket-controlled temperature of 0–5 °C over 3–4 hours; failure to maintain sub-ambient conditions leads to hydroxide-mediated displacement of the bromide at the 4-position, generating the des-bromo byproduct in quantities exceeding 2 area%, as determined by HPLC at 254 nm. Following acidification with 6 N HCl to pH 2.5–3.0 and extraction into ethyl acetate, the resulting 4-bromothiazole-5-carboxylic acid is isolated by crystallization from n-heptane/toluene (4:1) in 88–92% yield with >99.5% chemical purity. The carboxylic acid is subsequently activated with HATU (1.05 eq) and N-methylmorpholine (2.5 eq) in anhydrous DMF at -15 °C, then coupled with an array of heterocyclic amines to produce thiazole-4-carboxamide candidates that target bacterial cell division protein FtsZ. Process analytical technology (PAT) implementation includes ReactIR monitoring of the anhydride intermediate peak at 1820 cm⁻¹ to avoid dimeric anhydride formation, which is the primary yield-limiting impurity. Production campaigns conducted in a 2000 L glass-lined reactor (Pfaudler) with a retreat-curve impeller and jacket ∆T control of ±1 °C have consistently maintained the dimeric anhydride impurity below 0.15 area%. Residual solvent specifications conform to ICH Q3C(R8) Option 2 for THF (Class 2, PDE 7.2 mg/day) and DMF (Class 2, PDE 8.8 mg/day); in-process controls verify lot-specific content via headspace GC-FID per USP <467> Procedure A. The downstream amine coupling process also requires precautionary measures to exclude primary aliphatic amines that could undergo transesterification with the original ethyl ester contaminant, which is kept below 0.5% in the acid intermediate. The final thiazole-4-carboxamide series is supplied as a pre-clinical antibacterial intermediate under ICH Q7 GMP for active pharmaceutical ingredient starting materials, with extended stability data demonstrating no degradation when stored at -20 °C under argon for 24 months. Due to the genotoxic potential assessed per ICH M7(R1) for the bromoaromatic moiety, the specific carried-over level of ethyl 4-bromo-1,3-thiazole-5-carboxylate into the final amide must be controlled below 0.15% w/w through an efficient bicarbonate wash and a subsequent activated carbon treatment, confirmed by UPLC-UV at 270 nm.

Hydrolytic Ring-Opening Pathways Are Suppressed by Low-Temperature Amidation Protocols

Direct ammonolysis of the ester with 40% aqueous methylamine (1.5 eq) in methanol at a jacket-set temperature of 5 °C circumvents the saponification step entirely and yields N-methyl-4-bromo-1,3-thiazole-5-carboxamide, a key intermediate for the construction of SDHI (succinate dehydrogenase inhibitor) fungicide analogs. At temperatures exceeding 12 °C, the thiazole ring undergoes nucleophilic ring-opening initiated by methoxide attack at the C-2 position; the resultant thioamide-ester degradation species is observed by ¹H NMR as a characteristic multiplet at δ 5.2–5.4 ppm and must be controlled below 1.0 area%. The reaction is executed in a 3000 L stainless steel reactor (ANSI 316L) with a dyne-tuned mechanical seal suitable for the vapor pressure of methylamine. The methylamine solution is metered via a peristaltic pump over 90 minutes, maintaining the internal temperature at 4–6 °C with a jacket circulation of a 40% ethylene glycol-water mixture at -10 °C. After an additional 4-hour age period, the solvent is removed under reduced pressure (50 mbar, 35 °C bath) and the residue is subjected to a scraped thin-film evaporator (Pfaudler WFE, 0.5 m² surface area) to strip residual methylamine and methanol to a combined level of <100 ppm. The crude amide is recrystallized from cyclohexane/acetone (9:1) at -15 °C, yielding a product with >99.3% purity free of the ring-opened impurity. The terminal product, a 4-bromo-thiazole-5-carboxamide scaffold, serves as the electrophilic partner in a subsequent Suzuki coupling with tailor-made benzamide boronic esters to assemble compounds screening against Botrytis cinerea and Zymoseptoria tritici. Regulatory oversight follows the EPA 40 CFR Part 158 Subpart W guidelines for biochemical pesticide active ingredients; mutagenicity screening is performed according to OECD 471 (Ames test) with a required negative result at 5000 µg/plate. Additionally, the manufacture of intermediates intended for eventual agricultural formulation must comply with REACH (EC 1907/2006) substance identity and use description, and any shipment into the European Economic Area requires a completed REACH Article 31 safety data sheet with exposure scenario for the isolated intermediate.

Why Do Continuous-Flow Protocols Reduce Dehalogenation in Thiazole-5-Carboxylate Methanolysis?

Batch-mode transesterification of ethyl 4-bromo-1,3-thiazole-5-carboxylate with sodium methoxide in methanol accelerates hydrodebromination at prolonged residence times owing to localized base hotspots. Continuous-flow processing in a Corning Advanced-Flow G1 glass reactor (channel hydraulic diameter 1.0 mm, total internal volume 8.7 mL) suppresses this side reaction through rapid heat transfer and a residence time distribution narrowed to σ² < 0.05. A 0.5 M feedstock of the ethyl ester in anhydrous methanol is combined with a 0.525 M solution of sodium methoxide (1.05 eq) at a combined flow rate of 12.0 mL/min, yielding a mean residence time of 43 seconds at 90 °C and a system back-pressure of 7.5 bar to maintain single-phase flow. Under these conditions, conversion exceeds 99% and the des-bromo impurity is held below 0.10 area%, whereas a comparable batch run at 65 °C for 2 hours generates 2.3 area% of the dehalogenated species. The methyl ester product stream is quenched inline with a 1.0 M acetic acid solution in methanol at a 1:1 volumetric ratio, neutralized to pH 6.8–7.2, and concentrated using a wiped-film evaporator (UIC, 0.04 m²) under 25 mbar to afford methyl 4-bromo-1,3-thiazole-5-carboxylate as a low-melting crystalline solid. This intermediate is a versatile precursor for antifungal 14α-demethylase inhibitors; subsequent C-2 lithiation with LDA at -78 °C and trapping with an aryl aldehyde introduces the required substituted-methyl alcohol side chain. Processing equipment in contact with the methanolic methoxide stream must be fabricated from alloy C-276 or PTFE-lined stainless steel to resist caustic stress-corrosion cracking. The continuous-flow campaign is governed by the cGMP principles of ICH Q7 Section 12 (Validation of Process Steps) and the equipment qualification standard ASTM E2500-20; elastomeric seals exposed to the methanol-sodium methoxide mixture are specified according to FDA 21 CFR 177.2600 (peroxide-cured EPDM). The isolated methyl ester is stored under nitrogen at 2–8 °C with an established retest period of 12 months. Published data for pilot-scale continuous methanolysis of this specific bromothiazole ester configuration in a Corning G1 reactor remains limited, yet the principles of heat-transfer superiority over batch are well established in analogous halogenated heterocyclic ester systems.

During the Manufacture of Thiazole-Modified Nucleoside Prodrugs

Electrophilic displacement of the bromide with a protected 2′-deoxy-4′-thio-β-D-ribofuranose derivative containing a free anomeric thiol group is conducted in anhydrous DMF at 45 °C with K₂CO₃ (2.0 eq) as the acid scavenger, affording a 4-thioglycosyl thiazole-5-carboxylate ester as a prodrug precursor aimed at HCV NS5B polymerase. The thiol nucleophile is charged at 1.10 eq relative to the bromoester, and the reaction progress is monitored by TLC (silica gel 60 F₂₅₄, n-hexane/ethyl acetate 2:1) until the bromoester is no longer visible under 254 nm UV light. A temperature ceiling of 50 °C is strictly observed because the ester carbonyl is susceptible to nucleophilic attack by the thiolate anion at elevated thermal energy, leading to thioester transesterification and glycosidic bond cleavage. The crude product is diluted with ethyl acetate, washed with 5% aqueous brine to remove potassium carbonate and the bromide salt, and purified by silica gel flash chromatography (230–400 mesh, gradient from 12% to 35% ethyl acetate in n-hexane). The combined product fractions are concentrated on a rotary evaporator at 30 °C bath temperature and finally subjected to a suspension in n-heptane and filtration to give the thioether-linked nucleoside analog in 67–79% yield with >98.7% purity. The terminal entity is a masked phosphoramidate prodrug, which, upon intracellular activation, releases the thiazole-containing nucleotide analog. For this intermediate application, the manufacturing facility must ensure that any residual DMF is controlled to the ICH Q3C(R8) limit of 880 ppm (PDE 8.8 mg/day) before shipment to the next synthetic step. Furthermore, the halogen content from the bromide leaving group is quantified by ion chromatography after oxygen flask combustion (USP <735>) and must be < 0.05% w/w in the final dried product to avert corrosion in subsequent hydrogenation reactors. The synthesis campaign operates under the quality system elements of ISO 9001:2015, with specific change control authorization required for any alternate source of the protected thioglycoside, as trace aldehyde impurities from silyl protecting group degradation have been observed to inhibit the coupling to <30% conversion on a 15 kg scale.

Prerequisites for Preparing Organozinc Intermediates Compatible with the 5-Carboxylate Ester

Negishi cross-coupling utilizing an in-situ-generated (hetero)arylzinc chloride permits the introduction of functionalized aryl groups containing electrophilic substitution patterns that are incompatible with Suzuki conditions, provided the organozinc reagent is formed under strictly anhydrous conditions that do not trigger ethyl ester cleavage. The 4-bromo-1,3-thiazole-5-carboxylate ester is first activated with Rieke zinc (1.3 eq) in NMP/THF (1:4) at 0–5 °C for 30 minutes to yield the corresponding organozinc bromide; an exotherm to >12 °C during this step results in self-coupling homodimer impurity at levels above 5 area%. The catalyst, Pd₂(dba)₃ (1.0 mol%), is combined with XPhos (3.0 mol%) in a separate vessel and pre-stirred in minimal THF for 15 minutes to ensure the active Pd(0)-XPhos complex is fully formed before transfer. The aryl halide coupling partner is dissolved in the NMP/THF matrix and added dropwise over 45 minutes while the internal temperature is maintained at 50–55 °C; the cross-coupling then proceeds at 65 °C for a total cycle of 5–8 hours. Aqueous work-up with 10% citric acid and extraction into methyl tert-butyl ether, followed by neutralization with 5% sodium bicarbonate, preserves the ester function, which remains intact in >98% of the HPLC-detectable material. The isolated 4-(hetero)aryl thiazole-5-carboxylate ester is purified on a 50 cm ID silica gel column with a mobile phase of dichloromethane/ethyl acetate (95:5) and crystallized from acetonitrile at -20 °C; typical yields range from 65% to 83%. The product synthesized via this Negishi route serves as the monomeric building block for donor-acceptor conjugated polymers evaluated as the active layer in organic thin-film transistors (OTFTs), where the thiazole ring acts as an electron-deficient moiety to lower the LUMO level. Regulatory compliance for such electronic-grade intermediates falls under RoHS 2 (2011/65/EU) regarding the restriction of total bromine content; compliance is demonstrated through combustion ion chromatography per EN 14582:2016 with a threshold of 900 ppm for homogeneous materials. Additionally, the development protocols reference IEC 62321-6 for sample preparation and verification of polybrominated biphenyls and diphenyl ethers as not present. Inventory listing under REACH pre-registration for tonnage band 1–10 t/a must be completed with a lead registrant dossier including the exposure scenario for industrial use in polymer compounding.